Regeneron Pharma stock (US75886F1075): Active in competitive CD38 oncology landscape

Regeneron Pharma is advancing CD38 x CD3 bispecific antibodies in early clinical development amid a crowded field led by approved products from Janssen and Sanofi generating over $10B in myeloma revenue, per recent competitive analysis.

Regeneron Pharmaceuticals is developing CD38 x CD3 bispecific antibodies targeting multiple myeloma and other hematologic cancers, positioned as a fast-growing route in the maturing CD38 therapeutic landscape, according to PatSnap Eureka as of 2026. This format leverages T-cell engagement for enhanced tumor cell killing beyond traditional ADCC mechanisms. The company maintains a multi-target bispecific portfolio in multiple myeloma, highlighting its commitment to innovative immuno-oncology approaches relevant to US investors via Nasdaq listing.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Regeneron Pharmaceuticals, Inc.
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Tarrytown, New York, USA
• Core markets: US, Europe, global
• Key revenue drivers: Eylea, Dupixent, oncology pipeline
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharma: core business model

Regeneron Pharmaceuticals focuses on discovering, inventing, developing, manufacturing, and commercializing medicines for serious diseases, with a strong emphasis on monoclonal antibodies, bispecific antibodies, and gene therapies. The company collaborates with Sanofi on key products like Dupixent for immunology and Eylea for ophthalmology, which drive significant US market revenue. Its proprietary VelociSuite technologies accelerate research across therapeutic areas including oncology and rare diseases.

Regeneron operates from its Tarrytown, New York headquarters, with manufacturing sites supporting global supply. For US investors, the firm's Nasdaq listing (REGN) provides direct exposure to biotech innovation, particularly in high-growth areas like immuno-oncology where CD38 programs are advancing.

Main revenue and product drivers for Regeneron Pharma

Eylea and Eylea HD, vascular endothelial growth factor inhibitors, remain top revenue generators for retinal diseases, with strong US sales contributing to the company's market position. Dupixent, co-commercialized with Sanofi, targets atopic dermatitis, asthma, and other inflammatory conditions, showing robust growth in the US market according to company reports.

The oncology pipeline, including bispecific antibodies like the CD38 x CD3 candidate, represents future growth drivers. Regeneron has filed three CD38-related patents since January 2023, per PatSnap Eureka as of 2026, underscoring R&D intensity in hematology.

Industry trends and competitive position

The CD38 target in hematology features 129 active drug programs, 1,865 patent filings since January 2023, and 322 Phase 2/3 trials, with approved leaders Daratumumab (Janssen) and Isatuximab (Sanofi) generating over $10B annually in multiple myeloma. Regeneron's CD38 x CD3 bispecific is in early clinical stages, differentiating via T-cell engagement in a saturated naked antibody space entering biosimilar competition.

Bispecific formats like CD38 x CD3 are a strong growth route, with Regeneron alongside Xencor advancing programs. This positions Regeneron competitively in oncology for US investors tracking biotech trends in antibody engineering.

Why Regeneron Pharma matters for US investors

Listed on Nasdaq, Regeneron offers US investors exposure to leading-edge biotech with major revenue from domestic sales of Eylea and Dupixent. Its oncology pipeline, including CD38 bispecifics, taps into the US-dominated multiple myeloma market, where innovation drives premium valuations.

Conclusion

Regeneron Pharma continues to advance its CD38 x CD3 bispecific in early clinical development within a dynamic hematology landscape anchored by blockbuster approved therapies. Patent activity and pipeline progress highlight ongoing innovation, while core products sustain revenue amid competitive pressures. US investors follow these developments closely given the firm's Nasdaq presence and biotech sector relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.